A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Analyst Upgrades And CASGEVY Approval [Yahoo! Finance]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Yahoo! Finance
Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise and newer assets, including the approval of CASGEVY and orphan drug status for the kidney therapy povetacicept. See our latest analysis for Vertex Pharmaceuticals. Those upgrades and regulatory milestones have landed against a backdrop of steady share price gains, with the stock at US$468.41 and a 90 day share price return of 11.48%. The 5 year total shareholder return of 104.47% points to meaningful longer term compounding and suggests momentum has been building rather than fading. If Vertex's recent moves have you looking across the sector, this could be a good moment to scan other healthcare stocks that might fit a similar long term healthcare thesis. With Vertex trading at US$468.41 and sitting about 8% below one analyst price target and at a modelled intrinsic discount of roughly 36%, you have to ask: is there still a buying opportunity here, or is
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]Yahoo! Finance
- Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]Yahoo! Finance
- Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]Yahoo! Finance
- WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/3/25 - Beat
VRTX
Sec Filings
- 2/3/26 - Form 3
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- VRTX's page on the SEC website